A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design, rationale, and methods
This trial tests the hypothesis that adding dupilumab to omalizumab-facilitated mOIT will increase the likelihood of inducing sustained unresponsiveness and decrease mOIT-related adverse events.
Authors
- R. Sharon Chinthrajah (ORCID: https://orcid.org/0000-0003-2467-4256)
- Stephen J. Galli (ORCID: https://orcid.org/0000-0001-5736-5340)
- Sayantani Sindher (ORCID: https://orcid.org/0000-0003-0387-2800)
- Joy Laurienzo Panza
- Jackson P. Schuetz (ORCID: https://orcid.org/0000-0002-1053-2903)
- Stacey Skura Zedeck
- Olivia Raeber
- Kari Christine Nadeau (ORCID: https://orcid.org/0000-0002-2146-2955)
- Ramesh K. Sharma (ORCID: https://orcid.org/0000-0002-2637-1841)
- Margaret Woch
- Amanda Long
- Alkis Togias (ORCID: https://orcid.org/0000-0001-9009-5717)
- Lisa M. Wheatley
- Scott D. Boyd (ORCID: https://orcid.org/0000-0003-0963-044X)
- Elizabeth Kiernan (ORCID: https://orcid.org/0000-0002-1814-8017)
- J. Poyser
- K. Martinez (ORCID: https://orcid.org/0009-0003-7988-1866)
- Marleni Albarran
- Andrew R. Chin
- Dinara Bogetic
- J. H. Choi
- Stephanie A. Leonard (ORCID: https://orcid.org/0000-0002-0742-0126)
- Jianxia Tang (ORCID: https://orcid.org/0000-0002-7145-9922)
- B. Anderson
- A. Parry
- Catherine Feight
- A. Grissinger
- M. Garcia Llorett
Institutions
- National Institutes of Health (US)
- Harvard University (US)
- University of California, Los Angeles (US)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- National Institute of Allergy and Infectious Diseases (US)
- Stanford University (US)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/falgy.2025.1729111
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00